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Introduction
Merkel cell carcinoma (MCC)1 is a rare but highly 
aggressive type of skin cancer with increasing inci-
dence.2,3 In 2008 the MCC-responsible virus was 
discovered and termed Merkel cell polyomavirus 
(MCV).3 This virus is ubiquitous in the human 
population and seroprevalences around 75% are 
reported.4–6 It is usually non-oncogenic, but under 
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Abstract
Background: Merkel cell carcinoma (MCC) is a rare but very aggressive skin tumor that 
develops after integration of a truncated form of the large T-antigen (truncLT) of the Merkel 
cell polyomavirus (MCV) into the host’s genome. Therapeutic vaccination with dendritic cells 
(DCs) loaded with tumor antigens is an active form of immunotherapy, which intends to direct 
the immune system towards tumors which express the respective vaccination antigens.
Methods: Cytokine-matured monocyte-derived DCs of healthy donors and MCC patients were 
electroporated with mRNA encoding the truncLT. To permit major histocompatibility complex 
(MHC) class II next to class I presentation, we used an RNA construct in which the antigen was 
fused to a DCLamp sequence in addition to the unmodified antigen. To further improve their 
immunogenicity, the DCs were additionally activated by co-transfection with the constitutively 
active nuclear factor (NF)-κB activator caIKK. These DCs were used to stimulate autologous 
CD8+ T-cells or a mixture of CD4+ and CD8+ T-cells. Then the percentage of T-cells, specific for 
the truncLT, was quantified by interferon (IFN)γ ELISpot assays.
Results: Both the truncLT and its DCLamp-fusion were detected within the DCs by flow 
cytometry, albeit the latter required blocking of the proteasome. The transfection with caIKK 
upregulated maturation markers and induced cytokine production. After 2–3 rounds of 
stimulation, the T-cells from 11 out of 13 healthy donors recognized the antigen. DCs without 
caIKK appeared in comparison less potent in inducing such responses. When using cells 
derived from MCC patients, we could induce responses for 3 out of 5 patients; however, here 
the caIKK-transfected DCs did not display their superiority.
Conclusion: These results show that optimized DCs are able to induce MCV-antigen-specific 
T-cell responses. Therapeutic vaccination with such transfected DCs could direct the immune 
system against MCC.
Keywords: adoptive cellular immunotherapy, dendritic cells, large T-antigen, Merkel cell 
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certain circumstances, the viral genome can inte-
grate into the host cells’ genome and expresses a 
mutated and thus truncated form of one of its 
proteins, termed the large T-antigen (truncLT), 
while the expression of the other viral proteins is 
switched off.7 How this is initiated, is yet not fully 
understood, but UV irradiation, immune sup-
pression, and high age are associated with this 
process.8
The actual incidence of this cutaneous cancer is 
2–8 cases per million people per year in Europe 
and the USA2 and 16 cases per million people in 
Australia.9 The incidence rate has been constantly 
increasing since the 1980s.3,10 MCC is character-
ized by a high mortality of 46%.11 Satellite and 
lymphatic metastases develop rapidly, accompa-
nied by a reduction of the survival rates to below 
20%.11–13 Apart from surgical excision, no effec-
tive therapy existed until recently. Radio- and 
chemotherapy are usually only performed with a 
palliative intention.14 However, these interven-
tions did not improve the overall survival for stage 
III MCC patients.15 In 2015 this kind of treat-
ment in the context of clinical trials was still con-
sidered as standard of care for disseminated 
MCC.16 New hope has emerged, as current trials 
with checkpoint blockade antibodies (reviewed by 
Vandeven and Nghiem17) have shown promising 
results. This new type of immunotherapeutic 
antibody targets inhibitory receptors on T-cells 
and their ligands in order to enhance anti-tumor 
immune responses.18 The observed clinical suc-
cesses indicated that immunotherapy is suitable 
to target MCC and will probably become the new 
standard of care,19 but despite a high response 
rate, still not every patient responded to the new 
drugs. Therefore, it is necessary that additional 
treatment options or new combinations are 
evaluated.
One approach is to induce tumor-specific T-cells 
by vaccination with dendritic cells (DCs). DCs 
are an ideal tool for immunotherapy, because 
they are able to process and present tumor-
derived antigens, they prime, expand, and con-
trol-antigen-specific T-cells, and guide their 
differentiation as nature’s adjuvant.20 These cells 
were already used in many clinical trials,21 but 
they are subject to further optimization.
Artificial activation of the DCs by mRNA-
transfection with factors related to NF-κB activa-
tion resulted in improved immunogenicity.22–24 
We could show that cytokine-matured DCs, 
which were transfected with constitutively active 
IκB kinase β (caIKK), displayed functions associ-
ated with better immunogenicity and memory 
induction, like for example, interleukin (IL)-
12p70 secretion.25
For DC vaccines, a suitable target antigen is obvi-
ously of great importance. Such an antigen should 
be exclusively expressed in the malignant tissue, 
and ideally not be germline-encoded to avoid 
thymic tolerance. A certain protein size would be 
beneficial to facilitate enough T-cell epitopes 
within the antigen, and ideally such a protein 
should contribute to the malignant phenotype of 
the cancer cells. The truncLT combines these 
features making it an intriguing cancer vaccina-
tion antigen.
In this study, we examined the immunogenicity 
of truncLT-transfected DCs for immunotherapy 
and showed the induction of antigen-specific 
responses in CD8+ or CD4+ and CD8+ T-cells 
from healthy donors and MCC patients.
Material and methods
Any sequences, constructs, and raw data are 
available on request from the corresponding 
author.
Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) 
were purified from peripheral blood, obtained 
from healthy donors or MCC patients following 
informed consent and approval by the institu-
tional review board (Ethikkommision der 
Friedrich-Alexander- Universität Erlangen- 
Nürnberg, Erlangen, Germany: Ref. no. 4158 
and 4603, respectively) as described before.26 For 
the described priming experiments with healthy 
donor blood, between 400–500 ml peripheral 
blood was used, divided on 2 blood draws with a 
1 week interval. Blood draws from patients were 
kept lower (usually 60 ml in total) to avoid harm 
to the elderly and diseased patients. Blood was 
stored for less than 3 h in the presence of heparin 
or ethylenediaminetetraacetic acid (EDTA; 
Sigma-Aldrich, Steinheim, Germany) and sub-
jected to density centrifugation with lymphoprep 
(Axis-Shield PoC AS, Oslo, Norway). Cells were 
washed 3 times in Dulbecco's phosphate-buffered 
saline (DPBS; Lonza, Verviers, Belgium) con-
taining 1 mM EDTA at 282 g for 15 min, 189 g 
for 10 min and 114 g for 12 min at 4°C. An 
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additional washing step with RPMI 1640 (Lonza) 
at 149 g for 12 min was performed and cells were 
counted with a Neubauer hemocytometer and 
trypan blue staining (Sigma-Aldrich) before the 
cells were further processed. Approximately 0.8 
to 1.5 × 106 cells could be generated from 1 ml of 
blood.
Generation and maturation of DCs
The monocytes were isolated from the PBMCs by 
plastic adherence. A total of 3–4 × 107 PBMCs 
per 10 cm tissue culture dish (Falcon, Corning 
GmbH, Kaiserslautern, Germany) were incubated 
in 10 ml DC medium for 1 h at 37°C. DC medium 
consisted of Roswell Park Memorial Institute 
(RPMI) 1640 medium supplemented with 1% 
heat-inactivated non-autologous human plasma 
from individual donors (Transfusionsmedizin, 
Universitätsklinikum Erlangen, Erlangen, 
Germany) or heat-inactivated pooled human 
serum (Sigma-Aldrich), 2 mM L-glutamine 
(Lonza), and 20 mg/l gentamycin (Lonza). The 
non-adherent fraction (NAF) was removed by 
rinsing with RPMI 1640 and used for T-cell isola-
tion. Approximately 1–2 × 107 non-adherent cells 
were obtained from each dish. The adherent 
monocytes were differentiated to immature DCs 
over 6–7 d in DC medium supplemented with 800 
IU/ml granulocyte macrophage colony-stimulating 
factor (GM-CSF) (Miltenyi, Bergisch Gladbach, 
Germany), and 250 IU/ml IL-4 (Miltenyi) on days 
1, 3, and 5. On day 6 or 7 the DCs were matured 
by adding a cytokine cocktail of 200 IU/ml IL-1β 
(CellGenix, Freiburg, Germany), 1000 IU/ml 
IL-6 (CellGenix), 200 U/ml tumor necrosis factor 
(TNF) (Peprotech, Hamburg, Germany), and 1 
μg/ml prostaglandin E2 (PGE2) (Pfizer, Zurich, 
Switzerland) for another 24 h. One culture dish 
usually yielded between 1–2.5 × 106 cytokine-
matured DCs (cmDCs).
Isolation of T-cells
CD4+ and CD8+ T-cells were isolated from fresh 
and cryoconserved NAF, using anti-CD4 or anti-
CD8 MACS-beads (Miltenyi) respectively, 
according to the manufacturer’s instructions. The 
yield was between 5–10% for CD8+ and 10–20% 
for CD4+ T-cells. The isolated T-cells were cul-
tured overnight at a concentration of 1–2 × 106 
cells/ml in T-cell medium consisting of RPMI 
1640, 10% heat-inactivated human serum (Sigma-
Aldrich), 2 mM L-glutamine, 20 mg/l gentamycin, 
10 mM hydroxyethyl piperazineethanesulfonic 
acid (HEPES; PAA Labortechnik, Pasching, 
Austria), 1 mM sodium pyruvate (PAA), and 1% 
MEM non-essential amino acids (aa) (100×, 
PAA), supplemented with 20 U/ml IL-7 
(Peprotech) for CD8+ T-cells and additionally 
with 5 ng/ml IL-15 (R&D systems, Wiesbaden-
Nordenstadt, Germany) for CD4+ T-cells.
Cryoconservation
DCs and NAFs were cryopreserved by resus-
pending the cells in cold human serum albumin 
solution (20%, Sigma-Aldrich) at a maximum 
concentration of 5 × 106 cells/ml (DCs) or 5 × 
107 cells/ml (NAF). An equal volume of cryo-
preservation medium was added, consisting of 
55% human serum albumin solution (20%, 
Sigma-Aldrich), 20% dimethyl sulfoxide (Sigma-
Aldrich) and 25% glucose monohydrate solution 
(40%, Fresenius Kabi, Bad Homburg, Germany). 
Cells were then frozen at a speed of −1°C/min in 
a cryopreservation container (Nalgene, Rochester, 
NY, USA) to −80°C. Thawing was performed by 
mixing the cells with room temperature RPMI 
1640, washing them in at least 10 ml RPMI 1640, 
and transferring them to a cell culture dish con-
taining DC medium, supplemented with 
GM-CSF (800 IU/ml) and IL-4 (250 IU/ml) or 
T-cell medium, supplemented with IL-7. The 
cells were allowed to rest at 37°C for 1 h before 
further processing.
In vitro transcription of RNA
RNA was generated by in vitro transcription using 
the mMESSAGE mMACHINE T7 ULTRA 
Transcription Kit (Life Technologies, Carlsbad, 
CA, USA) and purified with an RNeasy Kit 
(Qiagen, Hilden, Germany) according to manu-
facturer’s instructions. The trLT construct con-
sisted of the aa 1–259 of the MCV large T-antigen 
fused to a myc-tag sequence. The trLT-DCL con-
struct consisted of the Lamp1 signaling peptide 
(aa 1–29) preceding the aa 1–246 of the MCV 
large T-antigen fused to the human DCLamp 
sequence27 and a myc-tag sequence. Codon-
optimized templates were generated by GeneArt 
(ThermoFisher Scientific, Schwerte, Germany) 
and cloned into the pGEM4Z64A RNA produc-
tion vector.28 The caIKK construct corresponds 
to caIKKβ described previously.25 The control-
DCL-RNA consisted of an irrelevant tumor anti-
gen (mutated BRAF and GNAQ), also framed by 
the Lamp1 signaling peptide and the DCLamp 
and myc-tag sequence. The complete nucleotide 
Therapeutic Advances in Medical Oncology 9(7)
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sequences of all production vectors are available 
upon request.
RNA electroporation of DCs and T-cells
RNA electroporation (EP) was performed as 
described.29 Centrifugation of DCs and T-cells 
was always performed for 10 min at 22°C and 149 
g or 233 g, respectively. DCs were transfected 
with the RNA amounts indicated in the particular 
experiment. Prestimulated T-cells were electropo-
rated26 without RNA, 50 or 150 µg/ml trLT-RNA, 
50 or 150 µg/ml trLT-DCL-RNA or 150 µg/ml of 
the control-DCL-RNA. For electroporation, cells 
were harvested in RPMI 1640, washed once 
in OptiMEM without phenol-red (Invitrogen, 
Karlsruhe, Germany), and then resuspended in 
OptiMEM with a maximal concentration of 6 × 
107 DCs/ml or 12 × 107 T-cells/ml (all at room 
temperature). Electroporation was performed in 4 
mm cuvettes (biolabproducts GmbH, Bebensee, 
Germany) with a Genepulser Xcell machine (Bio-
Rad, Munich, Germany). The conditions were: 
square-wave pulse, 500 V, and 1 ms for DCs or 
5 ms for T-cells, respectively.29
After transfection, DCs were rested at 37°C for 4 
h in DC medium supplemented with GM-CSF 
(800 IU/ml) and IL-4 (250 IU/ml), before using 
them for T-cell expansion or cryoconservation. 
Transfected T-cells were rested in T-cell medium 
for 1 h before being used for further experiments. 
The survival rate of the DCs was around 75% 
and over 50% when combined with cryoconser-
vation. The survival rate of the T-cells was 
between 60–80%.
Expansion of antigen-specific T-cells
Electroporated DCs were co-incubated with 
autologous T-cells, either pure CD8+ T-cells or a 
1:1 mixture of CD4+ and CD8+ T-cells, with 2 × 
106 T-cells and 2 × 105 DCs in 2 ml T-cell 
medium supplemented with IL-7 for 1 week. 
Excess DCs were cryoconserved for restimula-
tion. On the 2nd and the 4th day, 1000 IU/ml 
IL-2 and 10 ng/ml IL-7 were added and an addi-
tional 5 ng/ml IL-15, when CD4+ T-cells were 
present in the culture. After 1 week, the T-cells 
were harvested and used for the next round of 
expansion or for the read-out. For healthy donors, 
the 2nd stimulation was also performed with 
fresh, electroporated DCs. This in vitro assay uses 
only human autologous primary cells and hence 
can emulate the interaction between the DCs and 
the T-cells, but of course the situation within a 
living organism is much more complex and the 
involvement of other cell types is not covered.
Flow cytometric analysis of intracellular trLT-
construct expression
For intracellular detection of the introduced trLT 
and trLT-DCL, the electroporated DCs were 
treated with 0.5 µm bortezomib or were left 
untreated. At 4 h after electroporation the DCs 
were vortexed and fixed with 2% formaldehyde 
for 10 min at room temperature or overnight at 
4°C. After washing cells once with FACS buffer 
(DPBS with 1% fetal bovine serum (FBS) and 
0.2% sodium azide), they were incubated in 
chilled (−20°C) methanol (⩾99.9%) for 10 min. 
Afterwards, cells were washed twice with FACS 
buffer and then stained with the anti-myc-tag 
Alexa®488 mouse mAb (clone 9B11, NEB, 
Frankfurt am Main, Germany) in the dark. 
Immunofluorescence was detected using a 
FACScan cytofluorometer equipped with 
CellQuest software [Becton Dickinson (BD), 
Heidelberg, Germany]. Living cells were gated by 
forward and sideward scatter. Of note, is that this 
method only shows the amount of antigen within 
the cells, but does not show its turnover or the 
processing and presentation.
Flow cytometric analysis of surface marker 
expression on DCs
Mature DCs were electroporated without or with 
IKKβ-RNA as described above and harvested 24 
h, 48 h, or 72 h after transfection. Cells were 
stained at 4°C in FACS buffer for 30 min with the 
following antibodies: anti-CD40-FITC (BD), 
anti-CD40-PE (BD), anti-CD25-FITC (Cymbus 
Technologies, Southampton, Hampshire, United 
Kingdom or BD), anti-CD25-PE (BD), 
anti-CD70-PE (BD), anti-OX40L-PE (BD), anti-
CD80-FITC (BD), anti-CD83-PE (Miltenyi), 
anti-CCR7-FITC (R&D Systems), anti-CD86-
FITC (Cymbus Technologies), anti-CD86-PE 
(Miltenyi, BD), and anti-PD-L1-PE (eBioscience) 
and with matched isotype controls: IgG1-FITC 
(BD, Miltenyi), IgG1-PE (Miltenyi), IgG2a-
FITC (BD), IgG3-PE (eBioscience). The cells 
were then washed once with FACS buffer and 
were taken up in FACS buffer or a mixture of 
equal amounts of FACS-Fix (DPBS with 2% for-
maldehyde) and FACS buffer. Afterwards, the 
immunofluorescence was determined using a 
FACScan cytofluorometer equipped with Cell 
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Quest software (BD). The DCs were discrimi-
nated based on their size and granularity by gating 
in the forward and side scatter channels. The spe-
cific mean fluorescence intensities (specific MFI) 
were calculated by subtraction of the background 
mean fluorescence intensity obtained with the iso-
type control antibodies. All values were set in rela-
tion to the 24 h control condition to calculate the 
fold induction.
Cytokine analyses
Matured DCs were electroporated without or 
with caIKK-RNA as described above. The 
cytokine concentrations in the supernatant of the 
cells were analyzed 24 h after EP with a human 
inflammatory Cytometric Bead Array (CBA) 
from BD according to the manufacturer’s instruc-
tions. Absolute cytokine concentrations were 
determined from standard curves using the Excel 
software (Microsoft, USA). Negative values were 
set to 0.
Interferon γ-ELISpot assays
Interferon (IFN)γ-ELISpots were performed as 
described before.26 Anti-IFNγ-coated 96-well 
ELISpot plates (Mabtech, Hamburg, Germany) 
were washed once with DPBS (Lonza) and blocked 
for 1 h at 37°C with ELISpot medium, consisting 
of RPMI 1640 with 5 % heat-inactivated human 
serum, 2 mM L-glutamine, 20 mg/l gentamycin, 
and 10 mM HEPES. ELISpot assays were per-
formed using 5 × 105 prestimulated antigen-RNA 
electroporated T-cells in 200 μl ELISpot medium 
per well. T-cells, which were electroporated with-
out RNA, were used as controls. For peptide 
stimulation, 1 μg/ml trLT-peptides were added 
directly to the unelectroporated T-cells. We tested 
the human leukocyte antigen (HLA)-A*24:02 
restricted peptide EWWRSGGFSF,30 the HLA-
A*01 restricted peptide HSQSSSSGY,31 and the 
HLA-A*02 restricted peptides VIMMELNTL, 
SMFDEVDEAPI, and KLLEIAPNC31 in 9 of 
the donors, according to their HLA-A haplotype, 
but did not observe specific responses against any 
of them, except for one HLA-A24-donor, who 
showed a specific response to the HLA-A24:02-
restricted peptide, which was similar to the reac-
tion upon the trLT-RNA-transfection (data not 
shown). After 20 h of incubation at 37°C, the 
ELISpot plates were washed 6 times with DPBS 
and stained with horseradish peroxidase (HRP)-
conjugated anti-IFNγ antibody diluted 1:200 in 
DPBS with 0.5% FBS (PAA) for 2 h. The plates 
were washed again, and HRP activity was detected 
with a tetramethylbenzidine (TMB) substrate 
solution (Mabtech). ELISpot assays were evalu-
ated using the Zeiss ELISpot Reader and the KS 
ELISpot 4.13.0 software. This assay was previ-
ously described and validated in detail,26 and is 
well suitable to detect responses to naturally pro-
cessed HLA class I-restricted responses. However, 
this assay is not suitable to detect HLA class 
II-restricted responses, since the expression of 
HLA class II is very low upon the T-cells, except 
for the few activated ones, and, more importantly, 
the intracellularly expressed antigens will not enter 
the HLA class II pathway efficiently enough.
Results
Introduction of truncated large T-antigen 
constructs into cmDCs
To generate a DC-based therapeutic cancer vac-
cine against MCC, we expressed the virus-derived 
oncogenic truncLT in monocyte-derived cmDCs 
by mRNA electroporation, to transiently intro-
duce the antigen into the cells. For this purpose, 
we designed a construct, consisting of the coding 
sequence for the truncated form of the large 
T-antigen of the MCV, and a myc-tag to allow for 
intracellular staining [hereafter termed trLT; 
Figure 1(a)]. Another construct in addition con-
tained the signal peptide of Lamp1 and the 
sequence of DCLamp to facilitate class II presen-
tation in addition to class I presentation,27 [there-
after termed trLT-DCL; Figure 1(a)]. The 
constructs were transcribed in vitro to generate 
mRNA for electroporation of cmDCs. At 4 h 
after electroporation, the expression was deter-
mined by intracellular staining of the myc-tag 
[Figure 1(b) and (c)]. To inhibit rapid degrada-
tion by the proteasome, the proteasome inhibitor 
bortezomib was added. We detected satisfying 
expression levels of trLT, especially when we 
used 15 µg of RNA/100 µl cell suspension for 
electroporation [Figure 1(b) and (c)]. Expression 
levels were only slightly increased by blocking 
the proteasome [Figure 1(b) and (c)]. The trLT-
DCL, in contrast, was only detectable, when 
bortezomib was added, and only after electropo-
ration of 15 µg of mRNA [Figure 1(b) and (c)]. 
This indicates that the trLT-DCL protein is rap-
idly degraded by the proteasome, which may lead 
to rapid processing and presentation of the anti-
genic peptides. Hence, the low protein levels we 
detected, did not preclude us from further using 
the DCLamp-modified construct. For further 
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experiments, we decided to use 15 µg of RNA 
coding for the trLT and the trLT-DCL 
constructs.
Detection of antigen-specific T-cell responses 
to the truncated large T-antigen in healthy 
donors
To overcome the limitations of conventional 
cmDCs concerning repetitive T-cell stimulation, 
we decided to use our recently developed NF-κB-
activated designer DCs. Therefore, cmDCs were 
modified by the electroporation with constitu-
tively active (ca)IKK-RNA to make these cells 
more immunogenic by strongly activating the 
NF-κB signaling pathway (caIKK-DCs).25 This 
treatment increased the expression of several DC 
maturation markers and costimulatory surface 
molecules (CD40, CD25, CD70, OX40L, 
CD80, and CD86) over a period of 3 days, in 
comparison with cmDCs electroporated without 
caIKK-RNA [Figure 2(a)]. The caIKK-transfected 
DCs also produced higher quantities of the 
cytokines IL-8, TNF, IL-6, and IL-12p70, and a 
comparably small amount of IL-10 [Figure 2(b)]. 
This indicated that electroporation with caIKK-
encoding mRNA further activated the cmDCs, 
although they had already been matured with the 
cytokine cocktail.
caIKK-transfected DCs were either used as such 
(no antigen) or constructs coding for trLT or 
trLT-DCL were co-electroporated (Figure 3). 
These DCs were then used to stimulate autolo-
gous T-cells. We used either pure CD8+ T-cells 
or, since the DCLamp-modification should lead 
to presentation of helper epitopes, a 1:1 mixture of 
CD4+ and CD8+ T-cells. After 2, and after 3 
rounds of stimulation, each for 1 week, these 
T-cells were analyzed for their reactivity against 
trLT. To determine the number of antigen-spe-
cific CD8+ T-cells, we used a new readout-
method, established in our laboratory,26 which 
involved expression of the antigen within the 
T-cell population, resulting in major histocompat-
ibility complex (MHC) class I presentation of the 
antigen. By this, the T-cells themselves acted as 
antigen-presenting cells and there was no need for 
the addition of extra target cells. For this purpose, 
the T-cells out of the second and the third round 
of stimulation were taken and electroporated with 
mRNAs, coding for trLT, trLT-DCL, a control-
antigen with DCLamp-modification (control-
DCL), or were electroporated without RNA 
Figure 1. Introduction of trLT constructs into cmDCs.
(a) Schematic view of the antigen mRNA constructs. The  
truncLT (encoding amino acid 1–259) (MCV-LT 1–259) was 
fused C-terminally to a myc tag (Myc) for antibody detection. 
Additionally, the MCV-LT 1–246 was modified for MHC class 
II-restricted presentation by adding an N-terminal signaling 
peptide from Lamp1 (SIG) and C-terminally a sequence 
encoding human DCLamp.
(b and c) cmDCs were electroporated without RNA, with 
trLT RNA (trLT), or with trLT-DCLamp-RNA (trLT-DCL). The 
indicated quantities of RNA were used per 100 µl of cell 
suspension. After electroporation, the proteasome inhibitor, 
bortezomib, was added to achieve a better detection of 
the electroporated proteins. Intracellular staining was 
performed 4 h after electroporation with an anti-myc-
tag antibody. The geometric MFI and the percentage 
of positive cells were measured by flow cytometry. The 
average of 3 independent donors ± SEM is indicated (b). 
One representative histogram out of 3 independent donors, 
showing cmDCs, electroporated with 15 µg of RNA coding 
for the 2 different truncLT-constructs, is depicted (c).
cmDC, cytokine-matured dendritic cell; MHC, major 
histocompatibility complex; MFI, mean fluorescence 
intensity; SEM, standard error of the mean; truncLT, 
truncated form of the large T-antigen.
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(mock). Production of IFNγ over-night was meas-
ured by ELISpot, indicating an antigen-specific 
interaction of the cells.
We observed that stimulation of CD8+ T-cells 
[Figure 3(a)] and of the mixture of CD4+ and 
CD8+ T-cells [Figure 3(b)] with trLT-expressing 
Figure 2. Electroporation of cmDCs with caIKK-RNA upregulates surface markers and induces cytokine 
production.
cmDCs were electroporated without (no) or with 30 µg RNA/100 µl encoding caIKK (caIKK). (a) The expression kinetics of 
the indicated surface markers were determined 24 h (black bars), 48 h (dark grey bars), and 72 h (light grey bars) after 
electroporation by flow cytometry. The bars indicate the fold induction calculated towards the 24 h control condition of 9 
independent donors. The error bars indicate the SEM.
(b) The concentrations of IL-8, TNF, IL-6, IL-12p70, and IL-10 in the supernatants of the cells were determined 24 h after 
electroporation by a CBA. The bars indicate the mean values of 10 independent experiments. The error bars indicate the SEM.
CBA, Cytometric Bead Array; cmDC, cytokine-matured dendritic cell; IL, interleukin; SEM, standard error of the mean; TNF, 
tumor necrosis factor.
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IKK-DCs resulted in T-cells that produced the 
immunostimulatory cytokine IFNγ exclusively in 
response to the trLT. Especially after the third 
stimulation, there was a slight advantage appar-
ent, when CD4+ T-cells were also present, 
although the readout method was not suitable to 
detect the specific CD4+ T-cells.
A similar picture could be seen after stimulation 
with trLT-DCL-electroporated caIKK-DCs, 
but here a response against the DCLamp-part of 
the construct was also observed, because the 
control-RNA used in the readout, that possessed 
the DCLamp-sequence fused to a different 
tumor-antigen also induced IFNγ production 
(Figure 3). These responses were only detected 
after the stimulation with trLT-DCL and are 
therefore exclusive responses to the DCLamp 
sequence. Nevertheless, they did not reach the 
level of the antigen-specific responses and 
responses directed against the trLT were also 
induced.
After the third round of stimulation, the responses 
further increased (Figure 3), and the upper detec-
tion limit of the IFNγ-ELISpot was reached for 
some donors. In addition, the unspecific back-
ground, observed after the second stimulation in 
some donors, disappeared almost completely, 
indicating an even higher antigen-specificity of 
the stimulated T-cells (Figure 3). Nevertheless, a 
high donor to donor variability was observed. For 
2 out of 13 healthy donors we were not able to 
produce any antigen-specific response, whereas 
other donors showed very high antigen-specific 
T-cell responses.
These data demonstrate the high immunogenic 
potential of our trLT-DCs and our trLT-DCL-
transfected DCs to generate antigen-specific 
CD8+ T-cell responses in healthy donors. We 
believe that the usage of constructs processing the 
DCLamp-sequence will not have any disadvan-
tages but helps through activating CD4 mecha-
nisms, especially in vivo.
Comparison of caIKK-optimized cmDCs with 
conventional cmDCs
To prove that the caIKK-DCs are superior to 
conventional cmDCs, we compared the T-cell 
responses induced by ‘normal’ cmDCs with the 
ones that optimized designer caIKK-DCs could 
generate. We transfected cmDCs, either with the 
trLT-DCL alone, or together with caIKK-RNA. 
As above, these cells were then used to prime and 
stimulate autologous CD8+ T-cells or a 1:1 mix-
ture of CD4+ and CD8+ T-cells for week-long 
Figure 3. Detection of antigen-specific T-cell 
responses to the truncLT in healthy donors.
cmDCs from healthy donors were electroporated with 30 
µg RNA/100 µl cell suspension coding for caIKK alone (no 
antigen), or in combination with the indicated amounts 
of truncLT-RNA, either containing a DCLamp sequence 
(trLT-DCL) or not (trLT). At 4 h after electroporation these 
DCs were used to stimulate (stim) autologous CD8+ T-cells 
(a) or a 1:1 mixture out of CD4+ and CD8+ T-cells (b) for 
1 week. These T-cells were restimulated twice with the 
same electroporated DCs, which had been cryoconserved. 
After the second and third round of stimulation the T-cells 
were examined for their reactivity towards the trLT. To 
provide the antigen in the readout, the T-cells were 
electroporated with RNA encoding the truncLT, without 
(trLT) or with DCLamp (trLT-DCL). As controls, the T-cells 
were mock-electroporated (mock) or electroporated with 
a control-antigen construct, also containing the DCLamp-
encoding sequence (control-DCL). The electroporated 
T-cells were incubated overnight in an IFNγ ELISpot assay 
and the number of spot-forming units (sfu) per 500,000 
cells, used in the assay, was determined. The data from 
6–9 independent experiments are indicated; the different 
symbols represent different healthy donors.
cmDC, cytokine-matured dendritic cell; DC, dendritic cell;  
IFN, interferon; truncLT, truncated form of the large T-antigen.
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rounds of stimulation. After the third round of 
stimulation, the T-cells were subjected to the 
same readout as before by transfecting them with-
out RNA (mock), or with RNA encoding trTL, 
trLT-DCL, or a DCLamp-modified control anti-
gen (control-DCL). Afterwards, secretion of 
IFNγ was determined (Figure 4).
When we used the ‘normal’ cmDCs as stimula-
tors, we observed that the numbers of T-cells that 
specifically produced IFNγ was low or even unde-
tectable if pure CD8+ T-cells were stimulated 
[Figure 4(a)]. In contrast, we could observe high 
antigen-specific responses in 2 of 3 donors, 
when we used our optimized caIKK-transfected 
designer DCs [Figure 4(b)]. A similar picture was 
observed with the mixture of CD4+ and CD8+ 
responses [Figure 4(b)]. Here, only one donor 
showed an antigen-specific response if conven-
tional cmDCs were used. This picture changed 
again with the use of the caIKK-optimized designer 
DCs. With these DCs, a clear and high antigen-
specific CD8+ T-cell response could be observed 
after stimulation with the trLT- and the 
Figure 4. Comparison of caIKK-optimized cmDCs with conventional cmDCs.
cmDCs from healthy donors were electroporated with 15 µg/100 µl cell suspension truncLT-DCLamp (trLT-DCL) RNA alone 
or in combination with 30 µg of caIKK-RNA (caIKK). At 4 h after electroporation, these DCs were used to stimulate (stim) 
autologous CD8+ T-cells (a) or a 1:1 mixture out of CD4+ and CD8+ T-cells (b) for 1 week. These T-cells were restimulated 
twice with the same electroporated DCs, which had been cryoconserved. After the third round of stimulation the T-cells were 
examined for their reactivity towards the trLT. To provide the antigen in the readout, the T-cells were electroporated with 
RNA encoding the truncLT, without (trLT) or with DCLamp (trLT-DCL). As controls, the T-cells were mock-electroporated 
(mock) or electroporated with a control-antigen construct, also containing the DCLamp-encoding sequence (control-DCL). 
The electroporated T-cells were incubated overnight in an IFNγ ELISpot assay. The numbers of spots per 500,000 cells used 
in the assay are indicated. The data from 3 independent experiments are indicated; the different symbols represent the 
different experiments.
cmDC, cytokine-matured dendritic cell; DC, dendritic cell; IFN, interferon; truncLT, truncated form of the large T-antigen.
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trLT-DCL-RNA in most donors [Figure 4(b)]. 
As described above, again a DCLamp-specific 
response was induced (Figures 3 and 4).
These results indicate the efficacy of our caIKK-
DCs in combination with the trLT-DCL. 
Although this difference was not shown to be sta-
tistically significant, in combination with the 
results shown in Figure 2, this argues in favor of a 
better immunogenicity of the caIKK-transfected 
cmDCs. This is of obvious importance, thinking 
of a clinical application, where the effectiveness of 
DC vaccines could thus be further enhanced.
Responses against the truncated large 
T-antigen in patients
With respect to clinical application, it is impor-
tant to know what the situation looks like in MCC 
patients. Due to the fact that MCC patients are 
usually of advanced age, they often suffer from 
various other concomitant diseases and some-
times have an impaired immune system. In our 
case the collection of patient blood proved diffi-
cult and only small volumes could be taken. 
Nevertheless, we wanted to test if we were able to 
induce immune responses against the large 
T-antigen also with DCs and T-cells from 
patients. Moreover, we also wanted to check 
whether the higher potential of our caIKK-DCs 
that we observed with material from healthy 
donors was also observable with patient material. 
Therefore, cmDCs from MCC patient-derived 
blood were electroporated with caIKK-RNA and 
the RNA coding for the trLT-DCL, either alone 
or in combination. These cells were then used for 
the stimulation of CD8+ T-cells or a 1:1 mixture 
of CD4+ and CD8+ T-cells. Due to the very lim-
ited volumes of blood that could be drawn, not all 
conditions could be performed for each patient. 
After 2 rounds of stimulation, the T-cells then 
were analyzed using again the same readout 
method as above by transfecting them without 
RNA (mock), or with RNA encoding trLT, trLT-
DCL, or a DCLamp-modified control antigen 
(control-DCL). Afterwards, the number of 
antigen-specifically IFNγ-producing cells was 
determined. We had the opportunity to monitor 
the immune response after 3 rounds of stimula-
tion for only one patient.
We observed a very diverse picture of immune 
responses throughout all patients. Overall, 2 out 
of 5 patients did not respond at all [exemplary 
shown in Figure 5(a); patient #1]. This might be 
Figure 5. Responses against the trLT in patients.
cmDCs were generated out of whole blood from patients 
diagnosed with MCC with GM-CSF and IL-4 and matured 
with the standard maturation cocktail. Afterwards the 
cells were electroporated with caIKK-RNA or trLT-
DCL-RNA or with a combination of both. At 4 h after 
electroporation these DCs were used to stimulate 
autologous CD8+ T-cells (blue bars) or a 1:1 mixture out of 
CD4+ and CD8+ T-cells (red bars) for 1 week (depending on 
the material available). (a) These T-cells were stimulated 
for a second week with the same electroporated 
DCs which had been cryoconserved. Patient #1 is 
representative for patients #1 and #2 where no response 
was detected after 2 weekly stimulations. Patient #3 
showed a weak response and patient #4 a strong response 
after 2 weekly stimulations. (b) For patient #5, enough 
cells were generated to perform a third stimulation 
(shown as open bars). For readout, the T-cells were 
electroporated with RNA encoding the truncLT, without 
(trLT) or with DCLamp (trLT-DCL). As controls, the T-cells 
were mock-electroporated (mock) or electroporated with 
a control-antigen construct, also containing the DCLamp-
encoding sequence (control-DCL). The electroporated 
T-cells were incubated overnight in an IFNγ ELISpot assay. 
The numbers of spots per 500,000 cells used in the assay 
are indicated. Data from 4 different patients are shown; 
each panel represents one patient.
cmDC, cytokine-matured dendritic cell; DC, dendritic cell; 
GM-CSF, granulocyte macrophage colony-stimulating 
factor; IFN, interferon; IL, interleukin; MCC, Merkel cell 
carcinoma; truncLT, truncated form of the large T-antigen.
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due to the already exhausted phenotype of the 
cells and the partially very poor health status of 
several patients.
For patient #3, we stimulated a mixture of CD4+ 
and CD8+ T-cells and were able to detect weak 
responses against the trLT-DCL with 99 sfu in 
500,000 T-cells prestimulated with trLT-DCL-
transfected cmDCs and 18 sfu in 500,000 
T-cells prestimulated with trLT-DCL and 
caIKK-transfected cmDCs. The negative con-
trol did not exceed 1 sfu and no response to the 
trLT could be observed [Figure 5(a); patient 
#3]. For patient #4 we could detect strong 
T-cell responses to the trLT, either with or with-
out the DCLamp sequence [Figure 5(a); patient 
#4]. In contrast with healthy donors the addi-
tional electroporation of caIKK-RNA into the 
cmDCs of MCC patients did not enhance T-cell 
induction.
A similar pattern was observed if pure CD8+ 
T-cells were used [Figure 5(b)]. From patient #5 
we could generate enough DCs to perform a 
third stimulation of the T-cells. The conven-
tional DCs induced trLT-specific T-cell 
responses after the second round of stimulation, 
no matter whether trLT or trLT-DCL was used 
for the readout. These responses even increased 
after the third round of stimulation and came 
close to the maximum detection limit of the 
ELISpot [Figure 5(b)]. Interestingly, we also 
observed that the caIKK-DCs caught up with the 
conventional DCs after the third round of stimu-
lation [Figure 5(b)], indicating that these caIKK-
transfected DCs needed more time than ‘normal’ 
designer-DCs, but then continued to expand the 
specific T-cells.
In summary, our results indicate that optimized 
designer DCs like caIKK-DCs can induce 
immune responses against the trLT in cells from 
healthy donors and MCC patients. The advan-
tage of caIKK-transfected DCs did only emerge 
for the former, but not the latter. Ultimately clini-
cal trials are required to investigate whether a 
DC-based vaccine represents an additional treat-
ment option for MCC patients.
Discussion
In this study, we showed that mRNA-electropo-
rated DCs could induce specific T-cell responses 
against the MCV-truncLT in blood from healthy 
donors and MCC patients. This is an important 
step towards a DC-based cellular immunotherapy 
against MCC. Such an intended treatment would 
indeed be feasible: by performing a leukapheresis 
procedure, over 4 × 108 DCs can regularly be 
generated.32 We have performed this procedure 
successfully also with patients aged >75, so it 
would be possible with elderly MCC patients. 
Electroporation and subsequent cryoconserva-
tion will yield about 50% of these DCs as a vac-
cine,32 resulting in enough DCs to vaccinate 6 
times with 3 × 107 or 12 times with 15 × 106 
living DCs. The whole process can be performed 
under full good manufacturing practice (GMP), 
as we already did several times in the context 
of clinical trials with melanoma patients 
[ClinicalTrials.gov identifiers: NCT00074230 
and NCT01983748].
In therapeutic cancer vaccination, it is of great 
importance to choose a suitable target antigen. 
Therefore, the choice of a viral oncogenic antigen 
was quite obvious, because it is: (i) a ‘foreign’ anti-
gen and thus not exposed to central self-tolerance 
mechanisms, (ii) it is similar in various patients, 
enabling its general application in MCC, and (iii) 
it is relevant for the oncogenic phenotype, avoid-
ing the rise of antigen-loss variants of the tumor. 
The truncLT turned out to be less immunogenic 
than expected for a viral antigen. This may be due 
to the co-evolution of humans and MCV, so that 
the virus does not affect a healthy host while a 
seroprevalence of approximately 70% on average 
in the United States population is reported.33 
Pathogenic effects only occur if the virus inte-
grates into the host genome and undergoes an 
UV-induced mutation that uncouples the cell 
transformation from viral replication. In addition, 
this protein is not the immunodominant antigen 
of the virus, as it is not present in the viral parti-
cles. Therefore, the truncLT has been reported 
to display very little immunogenicity and the gen-
eration of immune responses appears to be very 
difficult in healthy hosts.31 MCV is, however, only 
one representative of a growing family of human 
polyomaviruses. Within the last few years 13 dif-
ferent members were found and more are proba-
bly to come (reviewed by Dalianis and Hirsch34 
and Nickeleit and Singh).35 Most of them show a 
seroprevalence of >50%. Hence a cross-reactivity 
of large T-antigen-specific T-cells would be pos-
sible. On the other hand, the part of the large 
T-antigen that shows the highest homology 
between the different viral species is lost due to the 
truncation. The low number of precursors, indi-
cated by the necessity to perform 1 or 2 restimula-
tions in vitro to receive reasonable numbers of 
specific T-cells argues against an existing memory 
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response against the truncLT in most healthy 
donors. The high numbers of specific T-cells we 
observed in some patients after 2 weeks of in vitro 
stimulation could indicate, in contrast, that an 
existing memory response was expanded.
Because truncLT is a challenging antigen it 
requires highly immunogenic DCs, for example, 
the caIKK-optimized designer cmDCs25 particu-
larly in healthy volunteers without preexisting 
specific T-cells31 and thus a requirement for 
priming. With such transfected cmDCs, T-cells, 
specific for this viral protein, were expanded from 
blood of most but not all healthy donors. The rea-
son that some donors did not respond might be 
that no suitable epitopes for their individual 
HLA-types could be generated from the antigen. 
This is in line with the previous observation that 
T-cell responses to a comprehensive number of 
truncLT-epitopes could be detected exclusively 
in MCC patients, but not in healthy donors.31
The finding that this viral antigen displays no 
higher immunogenicity than self-antigens (e.g. 
Wilms’ tumor protein 126) is also illustrated by 
the observation that the DCLamp-part of the 
trLT-DCL construct induced similar responses 
for several donors. This has been described before 
for other highly immunogenic DCs, designed and 
optimized for vaccination.36 Although it is possi-
ble that the additional activation of the NF-κB 
signaling pathway could already overcome the 
normally needed help,37 we decided to use 
DCLamp-modified constructs, to possibly also 
induce CD4+ T-cell-mediated responses.
In cellular immunotherapy, safety concerns 
always need to be considered. In this context, a 
transient expression of the truncLT by the deployed 
cells as well as a lack of integration into the host 
DNA is very important, because this protein is a 
tumor-driver, which could transform cells. This 
precludes any approach that could lead to stable 
expression, including DNA-based vaccination 
strategies, as well as viral transduction methods. 
On the other hand, the scarce immune responses 
against endogenously loaded truncLT-derived 
peptides31 asks for an expression of the complete 
antigen, enabling the antigen processing machin-
ery of the antigen-presenting cell (APC) to 
generate those epitopes that optimally fit the indi-
vidual HLA haplotype. To achieve this, mRNA 
transfection29 is the most suitable method.
The comparison of the caIKK-DCs with stand-
ard cmDCs revealed that the latter were also able 
to induce trLT-specific responses but with, in 
average, lower efficiency. Previously we had 
observed that our caIKK-DCs expanded naïve 
CD8+ T-cells less efficiently during priming than 
standard cmDCs, but upon restimulation, the 
caIKK-DC-stimulated T-cells were expanded 
more efficiently and overtook the others.25 These 
T-cells then reveal a highly active and probably 
memory-like phenotype. This would be of great 
advantage for the clinical application of DC vac-
cines against MCC.
Testing the immunogenicity of trLT-DCL-trans-
fected DCs with MCC patient-derived material 
was challenging, because only small volumes of 
blood could be taken from the aged and often dis-
eased patients and these patients often received 
treatments negatively influencing the quality of 
their immune cells. Nevertheless, we could induce 
responses which were higher after the 2nd stimu-
lation than in healthy donor blood. However, the 
caIKK-DCs did not display their superiority and 
with the blood of one patient, we even observed a 
clearly lower number of specific T-cells after 2 
weeks of stimulation. Here we could perform a 
3rd stimulation, and then observed a much better 
expansion with the caIKK-DCs, resulting in a 
similar overall number of trLT-specific T-cells 
after the 3rd stimulation. Furthermore, 2 out of 5 
patients showed no reaction at all, and blood we 
received from a patient under chemotherapy 
yielded no functional DCs and T-cells (data not 
shown). In summary, the data show that in sev-
eral patients trLT-specific T-cells exist, which 
can be readily expanded in vitro. This finding is in 
line with the high response rate of MCC to block-
ade of programmed cell death protein 1 (PD-1) 
or its ligand PD-L1,38 because this treatment 
requires preexisting cellular responses against the 
tumor to be efficient.
Hence, the next logical step would be to combine 
PD1- or PD-L1-inhibitors with therapeutic vacci-
nation. The checkpoint inhibitors as monotherapy 
already showed high benefits in the overall sur-
vival, and because there are no sufficient standard 
therapies available, experts in this field raised the 
justified request to use anti-PD-L1 or anti-PD-1 
antibodies as first line treatment against MCC 
from now on, even without further clinical phase II 
or III trials, because the results obtained so far are 
overwhelming.19 Unfortunately, still not all 
patients responded to this kind of therapy.38 For 
malignant melanoma, it was already shown that 
the combination of DC-based vaccines and check-
point inhibitors seems to increase the response 
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rates.39 Additionally, the combinatorial approach 
might allow reducing the dose of checkpoint-
blocking antibody. Especially in the aged and often 
multi-morbid patients any reduction of the side 
effects of this treatment would be desirable.
The clear-cut and now well understood mecha-
nism of how MCV is inducing MCC makes the 
truncLT a good role model for virus-derived 
oncogenic drivers, but it is not the only one. Also 
in the genesis of other human tumors, viruses 
play an important role, and the aspect of other 
viral antigens as targets for immunotherapy 
with DCs or other vaccine strategies is of great 
importance.40 Viral antigens expressed in human 
tumors possess exclusive features, which make 
them an ideal target for immunotherapy, and 
probably patients suffering from other tumor 
types could benefit from this concept.
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